Gyre Therapeutics Files 8-K on Financials
Ticker: GYRE · Form: 8-K · Filed: Feb 18, 2025 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | 8-K |
| Filed Date | Feb 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, company-update
TL;DR
Gyre Therapeutics dropped an 8-K on Feb 14th financials - check it out!
AI Summary
Gyre Therapeutics, Inc. filed an 8-K on February 18, 2025, reporting on its Results of Operations and Financial Condition as of February 14, 2025. The filing also includes Regulation FD Disclosures and Financial Statements and Exhibits. The company, formerly known as Catalyst Biosciences, Inc. and Targacept Inc., is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This 8-K filing provides crucial updates on Gyre Therapeutics' financial condition and operations, which are essential for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any immediate or significant risks.
Key Players & Entities
- GYRE THERAPEUTICS, INC. (company) — Registrant
- February 14, 2025 (date) — Date of earliest event reported
- February 18, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- San Diego, CA (location) — Principal executive offices
- CATALYST BIOSCIENCES, INC. (company) — Former company name
- TARGACEPT INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Gyre Therapeutics, Inc.'s Results of Operations and Financial Condition as of February 14, 2025, along with Regulation FD Disclosures and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on February 14, 2025.
What is Gyre Therapeutics, Inc.'s state of incorporation?
Gyre Therapeutics, Inc. is incorporated in Delaware.
What are the company's principal executive offices?
The company's principal executive offices are located at 12770 High Bluff Drive, Suite 150, San Diego, CA 92130.
What were some of Gyre Therapeutics' former company names?
Gyre Therapeutics, Inc. was formerly known as Catalyst Biosciences, Inc. and Targacept Inc.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 18, 2025 regarding GYRE THERAPEUTICS, INC. (GYRE).